Search
CELL BANK Website

Back Back
Cell No. : Cell Name
RCB2537 : TFK-1  update : 2020/09/24
CommentHuman cell line derived from extrahepatic bile duct carcinoma. TKG0367 (Deposited from Tohoku Univ.).
Comment from the depositor
Terms and conditionsThere is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, a prior written permission of the DEPOSITOR or the RIKEN BRC is necessary.
Remarks
Order Form Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, Category I and II, depending on the sort of user institutions and the purposes of use.Please use an appropriate MTA(to see).In case of Restriction "a" or "f", please contact RIKEN BRC(cellbank.brc@riken.jp) regarding any kind of for-profit use.
Basic information Depositor Fukuda, Hiroshi
Originator Saijyo, S.
Year of deposit 2007
Original cell TKG0367
Animal human < Mammals
Genus Homo
Species sapiens
Gender Male
Age at sampling 63 years
Tissue common bile duct
Case history papillary adenocarcinoma,
Classification cancer
History Cell Resource Center for Biomedical Research, Tohoku University(TKG0367)
Lifespan infinite
Morphology epithelial-like
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Medium and additives RPMI1640 + 10% FBS
Antibiotics Free
Passage method 0.25% trypsin
Culture information Passage ratio 1 : 6 split
SC frequency Subculture : once/week, Medium Renewal : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
STR(human) OK
Virus (HBV) (-)
Virus (HCV) (-)
Isozyme LD, NP
Images
deposit info
lot info
Reference information Reference 3
User's Publication 25


To topTop
Reference
5036  Kodama H, Suzuki M, Katayose Y, Shinoda M, Sakurai N, Takemura S, Yoshida H, Saeki H, Ichiyama M, Tsumoto K, Asano R, Kumagai I, Imai K, Hinoda Y, Matsuno S, Kudo T.  Mutated SEA-D227A-conjugated antibodies greatly enhance antitumor activity against MUC1-expressing bile duct carcinoma.  Cancer Immunol Immunother  2001  50(10):539-48  PubMed ID: 11776376
5035  Sakurai N, Kudo T, Suzuki M, Tsumoto K, Takemura S, Kodama H, Ebara S, Teramae A, Katayose Y, Shinoda M, Kurokawa T, Hinoda Y, Imai K, Matsuno S, Kumagai I.  SEA-scFv as a bifunctional antibody: construction of a bacterial expression system and its functional analysis.  Biochem Biophys Res Commun  1999  256(1):223-30  PubMed ID: 10066451
5034  Saijyo S, Kudo T, Suzuki M, Katayose Y, Shinoda M, Muto T, Fukuhara K, Suzuki T, Matsuno S.  Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1.  Tohoku J Exp Med  1995  177(1):61-71  PubMed ID: 8693487

To topTop
User's Publication
12014  Somchai P, Phongkitkarun K, Kueanjinda P, Jamnongsong S, Vaeteewoottacharn K, Luvira V, Okada S, Jirawatnotai S, Sampattavanich S.  Novel Analytical Platform For Robust Identification of Cell Migration Inhibitors.  Sci Rep  2020    PubMed ID: 31969633
12036  San TT, Khaenam P, Prachayasittikul V, Sripa B, Kunkeaw N, Chan-On W.  Curcumin enhances chemotherapeutic effects and suppresses ANGPTL4 in anoikis-resistant cholangiocarcinoma cells.  Heliyon  2020    PubMed ID: 32051864
12044  Fukuda Y, Asaoka T, Eguchi H, Yokota Y, Kubo M, Kinoshita M, Urakawa S, Iwagami Y, Tomimaru Y, Akita H, Noda T, Gotoh K, Kobayashi S, Hirata M, Wada H, Mori M, Doki Y.  Endogenous CXCL9 affects prognosis by regulating tumor-infiltrating natural killer cells in intrahepatic cholangiocarcinoma.  Cancer Sci.  2020    PubMed ID: 31799781
12163  Aman Tedasen, Araya Khoka, Siribhorn Madla, Somchai Sriwiriyajan, Potchanapond Graidist  Anticancer effects of piperine-free Piper nigrum extract on cholangiocarcinoma cell lines  Pharmacognosy Magazine  2020   
11476  Wei K, Li M, Zöller M, Wang M, Mehrabi A, Hoffmann K.  Targeting c-MET by Tivantinib through synergistic activation of JNK/c-jun pathway in cholangiocarcinoma.  Cell Death Dis  2019    PubMed ID: 30850583
11552  Yu J, Shi L, Shen X, Zhao Y.  UCP2 regulates cholangiocarcinoma cell plasticity via mitochondria-to-AMPK signals.  Biochem. Pharmacol.  2019    PubMed ID: 31085159
10816  Ota Y, Takahashi K, Otake S, Tamaki Y, Okada M, Aso K, Makino Y, Fujii S, Ota T, Haneda M.  Extracellular vesicle-encapsulated miR-30e suppresses cholangiocarcinoma cell invasion and migration via inhibiting epithelial-mesenchymal transition.  Oncotarget  2018  9:16400-16417  PubMed ID: 29662654
10834  Kawamoto M, Umebayashi M, Tanaka H, Koya N, Nakagawa S, Kawabe K, Onishi H, Nakamura M, Morisaki T.  Combined Gemcitabine and Metronidazole Is a Promising Therapeutic Strategy for Cancer Stem-like Cholangiocarcinoma.  Anticancer Res.  2018  38:2739-2748  PubMed ID: 29715094
10838  Huang CK, Iwagami Y, Zou J, Casulli S, Lu S, Nagaoka K, Ji C, Ogawa K, Cao KY, Gao JS, Carlson RI, Wands JR.  Aspartate beta-hydroxylase promotes cholangiocarcinoma progression by modulating RB1 phosphorylation.  Cancer Lett.  2018  429:1-10  PubMed ID: 29733964
11090  Ishigami K, Nosho K, Koide H, Kanno S, Mitsuhashi K, Igarashi H, Shitani M, Motoya M, Kimura Y, Hasegawa T, Kaneto H, Takemasa I, Suzuki H, Nakase H.  MicroRNA-31 reflects IL-6 expression in cancer tissue and is related with poor prognosis in bile duct cancer.  Carcinogenesis  2018  39(9):1127-1134  PubMed ID: 29860474
11166  Okumura Y, Noda T, Eguchi H, Sakamoto T, Iwagami Y, Yamada D, Asaoka T, Wada H, Kawamoto K, Gotoh K, Kobayashi S, Takeda Y, Tanemura M, Umeshita K, Doki Y, Mori M.  Hypoxia-Induced PLOD2 is a Key Regulator in Epithelial-Mesenchymal Transition and Chemoresistance in Biliary Tract Cancer.  Ann. Surg. Oncol.  2018  25(12):3728-3737  PubMed ID: 30105440
4244  Nam AR, Jin MH, Park JE, Bang JH, Oh DY, Bang YJ.  Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer.  Cancer Res Treat  2018    PubMed ID: 30514066
4245  Nam AR, Kim JW, Park JE, Bang JH, Jin MH, Oh DY, Bang YJ.  Jab1 Silencing Inhibits Proliferation and Sensitizes to Cisplatin in Biliary Tract Cancer.  Cancer Res Treat  2018    PubMed ID: 30282449
4339  Mori A, Masuda K, Ohtsuka H, Shijo M, Ariake K, Fukase K, Sakata N, Mizuma M, Morikawa T, Hayashi H, Nakagawa K, Motoi F, Naitoh T, Fujishima F, Unno M.  FBXW7 modulates malignant potential and cisplatin-induced apoptosis in cholangiocarcinoma through NOTCH1 and MCL1.  Cancer Sci.  2018    PubMed ID: 30302867
4360  Ohashi T, Eguchi H, Kawamoto K, Konno M, Asai A, Colvin H, Ueda Y, Takaoka H, Iwagami Y, Yamada D, Asaoka T, Noda T, Wada H, Gotoh K, Kobayashi S, Koseki J, Satoh T, Ogawa K, Doki Y, Mori M, Ishii H.  Mitochondrial pyruvate carrier modulates the epithelial-mesenchymal transition in cholangiocarcinoma.  Oncol. Rep.  2018  39(3):1276-1282  PubMed ID: 29286150
10312  Račkauskas R, Zhou D, Ūselis S, Strupas K, Herr I, Schemmer P.  Sulforaphane sensitizes human cholangiocarcinoma to cisplatin via the downregulation of anti-apoptotic proteins.  Oncol. Rep.  2017  37:3660-3666  PubMed ID: 28498473
5767  Ito M, Sun S, Fukuhara T, Suzuki R, Tamai M, Yamauchi T, Nakashima K, Tagawa Y, Okazaki S, Matsuura Y, Wakita T, Suzuki T.  Development of hepatoma-derived, bidirectional oval-like cells as a model to study host interactions with hepatitis C virus during differentiation.  Oncotarget  2017  8(33):53899-53915  PubMed ID: 28903311
9515  Sakamoto T, Kobayashi S, Yamada D, Nagano H, Tomokuni A, Tomimaru Y, Noda T, Gotoh K, Asaoka T, Wada H, Kawamoto K, Marubashi S, Eguchi H, Doki Y, Mori M.  A Histone Deacetylase Inhibitor Suppresses Epithelial-Mesenchymal Transition and Attenuates Chemoresistance in Biliary Tract Cancer.  PLoS ONE  2016  11:e0145985  PubMed ID: 26726879
9668  Nam AR, Kim JW, Park JE, Bang JH, Jin MH, Lee KH, Kim TY, Han SW, Im SA, Kim TY, Oh DY, Bang YJ.  Src as a Therapeutic Target in Biliary Tract Cancer.  Mol. Cancer Ther.  2016  15:1515-24  PubMed ID: 27196758
9700  Heits N, Heinze T, Bernsmeier A, Kerber J, Hauser C, Becker T, Kalthoff H, Egberts JH, Braun F.  Influence of mTOR-inhibitors and mycophenolic acid on human cholangiocellular carcinoma and cancer associated fibroblasts.  BMC Cancer  2016  16:322  PubMed ID: 27206490
3735  Saha SK et al  Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.  Cancer Discov  2016  6(7):727-39  PubMed ID: 27231123
7201  Fujimori T, Kato K, Fujihara S, Iwama H, Yamashita T, Kobayashi K, Kamada H, Morishita A, Kobara H, Mori H, Okano K, Suzuki Y, Masaki T.  Antitumor effect of metformin on cholangiocarcinoma: In vitro and in vivo studies.  Oncol. Rep.  2015  34:2987-96  PubMed ID: 26398221
7429  Nakamura K, Nakabayashi K, Htet Aung K, Aizawa K, Hori N, Yamauchi J, Hata K, Tanoue A.  DNA methyltransferase inhibitor zebularine induces human cholangiocarcinoma cell death through alteration of DNA methylation status.  PLoS ONE  2015  10:e0120545  PubMed ID: 25799509
4891  Peraldo Neia C, Cavalloni G, Balsamo A, Venesio T, Napoli F, Sassi F, Martin V, Frattini M, Aglietta M, Leone F.  Screening for the FIG-ROS1 fusion in biliary tract carcinomas by nested PCR.  Genes Chromosomes Cancer  2014  53(12):1033-40  PubMed ID: 25231053
3722  Ohashi H, Adachi Y, Yamamoto H, Taniguchi H, Nosho K, Suzuki H, Arimura Y, Imai K, Carbone DP, Shinomura Y.  Insulin-like growth factor receptor expression is associated with aggressive phenotypes and has therapeutic activity in biliary tract cancers.  Cancer Sci  2012  103(2):252-61  PubMed ID: 22044563



Back Back Return Top Page